US 11,883,525 B2
Bioerodible polyester polymer axitinib ocular implants and related methods of use
Patrick Michael Hughes, San Clemente, CA (US); James Shiah, San Clemente, CA (US); Jack Xie, San Clemente, CA (US); and Jia-Ying Yang, San Clemente, CA (US)
Assigned to DOSE MEDICAL CORPORATION, San Clemente, CA (US)
Filed by Dose Medical Corporation, San Clemente, CA (US)
Filed on May 29, 2020, as Appl. No. 16/888,384.
Claims priority of provisional application 62/855,666, filed on May 31, 2019.
Prior Publication US 2020/0375889 A1, Dec. 3, 2020
Int. Cl. A61K 9/00 (2006.01); A61K 47/34 (2017.01); A61K 31/4439 (2006.01)
CPC A61K 9/0019 (2013.01) [A61K 9/0051 (2013.01); A61K 31/4439 (2013.01); A61K 47/34 (2013.01)] 13 Claims
OG exemplary drawing
 
1. An implant comprising:
axitinib; and
a bioerodible polyester polymer blend comprising at least two polymers, wherein the bioerodible polyester polymer blend comprises an acid or ester end group polylactic acid (PLA) and an acid or ester end group poly-D,L-lactide-co-glycolide (PLGA), and wherein at least one of the two polymers comprises an ester end group,
wherein the PLA is selected from polymers with an inherent viscosity selected from between about 0.16 dl/g to about 0.35 dl/g as measured in 0.1% chloroform (25 ° C., Ubbelohde) size 0 capillary viscometer, and
wherein the axitinib is present in the implant in an amount selected from a range of between about 5 and about 80 percent (w/w).